证券代码：300677 证券简称：英科医疗 公告编号：2024-069 英科医疗科技股份有限公司 第三届监事会第二十一次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第三届监事会 第二十一次会议于 2024 年 7 月 19 日在公司会议室以通讯方式召开， 会议通知已于 2024 年 7 月 16 日以专人送达、电子邮件、传真或即时 通讯工具等形式向全体监事发出。会议由公司监事会主席唐烨先生召 集和主持，本次会议应出席监事 3 名，实际出席会议监事 3 名。会议 的召集和召开符合《中华人民共和国公司法》《英科医疗股份有限公 司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于2022年限制性股票激励计划第二个解除限售 期公司层面业绩未达标暨回购注销部分限制性股票的议案》 授但尚未解锁的限制性股票合计1,724,400股进行回购注销，该事项符 合《上市公司股权激励管理办法》和公司《2022年限制性股票激励计 划（草案）》的相关规定，且董事会审议本次回购注销限制性股票的 程序 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-073 英科医疗科技股份有限公司 特别提示： 本次聘任会计师事务所事项符合《国有企业、上市公司选聘会计 师事务所管理办法》（财会〔2023〕4 号）的相关规定。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 7 月 19 日召开第三届董事会第二十三次会议和第三届监事会第二十一 会议，审议通过了《关于公司聘任 2024 年度会计师事务所的议案》， 同意继续聘任普华永道中天会计师事务所（特殊普通合伙）（以下简 称"普华永道中天"）为公司 2024 年度财务报表及内部控制审计机 构；本议案尚需提交公司 2024 年第二次临时股东大会审议。 现将相关事项公告如下： 一、拟聘任会计师事务所事项的情况说明 普华永道中天是一家符合《中华人民共和国证券法》规定的审计 机构，具备为上市公司提供审计服务的经验和能力，能够满足公司财 务报表和内部控制审计工作要求。 公司聘请普华永道中天为公司审计机构以来，其工作勤勉尽责， 坚持公允、客观的态度进行独立审计，较好地完成了公司各项审计工 作。 二、拟聘任会计师事务所基本信息 关于聘任 2024 年度会计师事 ...

Profit Growth - Net profit attributable to shareholders of the listed company is expected to be between RMB 550 million and RMB 620 million, representing a year-on-year increase of 87.61% to 111.49%[13] - Net profit after deducting non-recurring gains and losses is expected to be between RMB 450 million and RMB 520 million, representing a year-on-year increase of 163.66% to 204.67%[13] Production Efficiency - The company's capacity utilization rate reached 100% during the reporting period[14] - The company has continuously upgraded production line technology, improving line speed and reducing energy consumption, thereby lowering production costs and enhancing profitability[9] Market and Pricing - The average selling price of disposable nitrile gloves and disposable PVC gloves increased compared to the same period last year[14] - Industry-wide capacity utilization rates have generally improved, and the supply-demand relationship is gradually returning to balance[14] Revenue and Currency Impact - The company's main sales revenue comes from overseas, and the appreciation of the US dollar had a positive impact on the company's performance in the first half of 2024[3]

证券代码：300677 证券简称：英科医疗 公告编号：2024-066 英科医疗科技股份有限公司 关于参与投资常州云常股权投资中心（有限合伙） 的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、投资基金概述 英科医疗科技股份有限公司（以下简称"公司"）境外全资子公 司英科医疗用品（香港）有限公司（以下简称"英科香港"）通过合 格境外有限合伙人机制，认缴设立广西自贸区云壮创业投资中心（有 限合伙）（以下简称"广西云壮"）。广西云壮作为有限合伙人之一， 以自有资金投资常州云常股权投资中心（有限合伙）及平行进行投资 的其他合伙企业（以下简称"合伙企业"或"基金"）。合伙企业的 目标总认缴出资额为人民币 120,000 万元（币种为人民币，下同）， 最高认缴出资总额为不超过 180,000 万元，本轮募集认缴出资额为不 超过 70,000 万元；英科香港将认缴出资 13,000 万元，通过广西云壮 投入合伙企业。具体内容详见公司于 2021 年 11 月 19 日刊登在巨潮 资讯网（www.cninfo.com.cn）的《关于参与投资常州云常股权投资中 心（有 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-065 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股东大会 审议通过之日起至下一年度股东大会召开时止。具体内容详见刊登于 巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请 授信额度及担保事项的公告》《2023 年度股东大会决议公告》（公告 编号：2024-036、2024-050）。 ...

关于公司回购股份实施结果的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、英科医疗科技股份有限公司（以下简称"公司"）回购股份方 案实施结果：截至 2024 年 7 月 13 日，公司根据本次回购股份方案通 过股份回购专用证券账户以集中竞价交易方式累计回购公司股份 4,504,300 股，占公司当前总股本的 0.6952%，最高成交价为 23.75 元 /股，最低成交价为 21.35 元/股，成交总金额为人民币 100,015,581.00 元（不含交易费用）。 2、截至本公告披露日，公司本次股份回购方案实施完毕。公司 本次回购股份的资金来源、使用资金总额、回购方式、回购价格及回 购实施期限等，与公司董事会审议通过的回购方案不存在差异。公司 实际回购金额已达回购方案中的回购资金总额下限，且未超过回购资 金总额上限，本次回购符合公司既定的回购股份方案及相关法律法规 的要求。 证券代码：300677 证券简称：英科医疗 公告编号：2024-064 英科医疗科技股份有限公司 公司于 2023 年 7 月 13 日召开第三届董事会第十五次会议和第 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 34.73 CNY per share, based on a 22x PE valuation for 2024 [110]. Core Insights - The company, YK Medical, is a leading player in the disposable glove industry, focusing on medical consumables and rehabilitation care products, with a significant emphasis on nitrile gloves. The company has shown substantial revenue growth and market share expansion, particularly during the global health crisis from 2020 to 2021, and is expected to continue benefiting from the recovery in global glove demand [27][41]. - In 2023, the company achieved total revenue of 6.919 billion CNY, with medical protective products accounting for 89.3% of sales. The overseas business represented 86.7% of total revenue, indicating a strong international presence [29][30]. - The report highlights the performance advantages of nitrile gloves over PVC gloves, including better chemical resistance, comfort, and lower allergy risk, which positions nitrile gloves as a key growth product in the disposable glove market [33][39]. Summary by Sections Company Overview - YK Medical has a total production capacity of 79 billion gloves, with 48 billion nitrile gloves and 31 billion PVC gloves, ranking first among domestic manufacturers and second globally [62][88]. - The company has invested in advanced automated production lines, significantly reducing labor and energy consumption while maintaining high product quality [88]. Market Dynamics - The global demand for disposable gloves is expected to stabilize and grow, driven by increased health awareness and regulatory standards in various industries [41][82]. - The market share of nitrile gloves has increased from 31.6% in 2017 to 35.6% in 2022, with projections to reach 37.1% by 2025, indicating strong growth potential for this product category [39][41]. Financial Performance - The company reported a compound annual growth rate (CAGR) of 34.8% in revenue from Q1 2019 to Q1 2024, reflecting robust growth despite a decline in glove prices post-2021 [27][29]. - The gross margin for Q1 2024 was 20.65%, higher than competitors, indicating effective cost management and production efficiency [68]. Production and Cost Structure - The company has strategically positioned itself in the upstream supply chain by investing in nitrile latex production, which helps mitigate raw material price volatility [70][92]. - The use of clean coal as the primary energy source provides a cost advantage over competitors relying on natural gas, with coal prices being significantly lower [96]. Future Outlook - Revenue projections for 2024 to 2026 are 9.295 billion CNY, 10.801 billion CNY, and 11.970 billion CNY, respectively, with growth driven primarily by nitrile glove sales [103]. - The company plans to expand its overseas production capacity to mitigate tariff impacts and leverage lower labor costs in Southeast Asia [79][100].

Investment Rating - The report gives a "Buy" rating with a target price of RMB 34.73 per share, based on a 22x PE valuation for 2024 and a 12-month target market cap of RMB 22.5 billion [19][106] Core Views - The company is a leader in the disposable glove industry, with significant advantages in production scale, cost control, and market share [13][38] - The company's revenue and profitability are expected to recover and grow steadily from 2024 to 2026, driven by capacity expansion, cost reduction, and rising export prices [19][81] - The company has a strong competitive position in the nitrile glove segment, with a leading market share and higher profitability compared to peers [38][157] Capacity and Expansion - The company has a total glove production capacity of 79 billion pieces, including 48 billion nitrile gloves and 31 billion PVC gloves, ranking first among domestic manufacturers [1][176] - The company plans to further expand its capacity in Anhui, Shandong, and Vietnam, with a target of reaching 64 billion nitrile gloves by 2026 [82][119] - The company has sufficient capital reserves to support its expansion plans, with a cash balance of RMB 7.22 billion as of 2023 [1][92] Cost Advantages - The company has vertically integrated into upstream raw materials, controlling two nitrile latex producers and investing in two others, which helps reduce procurement costs and improve product quality [70][162] - The company uses clean coal as its primary energy source, which is significantly cheaper than natural gas used by competitors, providing a cost advantage in energy consumption [5][165] - The company has invested in a cogeneration project in Anhui, which is expected to further reduce energy costs and improve efficiency [96] Market and Demand - Global demand for disposable gloves is expected to grow steadily, driven by increasing health awareness and stricter regulations in medical, industrial, and food sectors [58][174] - The company's export prices for nitrile gloves have shown signs of recovery, with the average export price reaching USD 16.57 per thousand pieces in May 2024, up 4.0% month-on-month [136][175] - Emerging markets, particularly China, have significant growth potential in disposable glove usage, with per capita consumption in China at only 9 pieces in 2020, compared to 317 in the Netherlands and 300 in the US [8][174] Financial Performance - The company's revenue is expected to grow from RMB 9.295 billion in 2024 to RMB 11.970 billion in 2026, with net profit increasing from RMB 1.022 billion to RMB 1.472 billion over the same period [3][81] - The company's gross margin improved to 20.65% in Q1 2024, higher than peers, and is expected to further increase to 21.4% by 2026 due to rising prices and cost reductions [1][81] - The company's ROE is projected to rise from 6.03% in 2024 to 7.61% in 2026, driven by improved profitability and efficient capital utilization [3][92] International Expansion - The company has established a production base in Vietnam to mitigate tariff risks and take advantage of lower labor costs, with a planned capacity of 8.82 billion gloves [49][172] - The company is accelerating overseas capacity expansion to reduce the impact of potential US tariff increases on nitrile gloves, which could rise from 7.5% to 25% by 2026 [76][172]

英科医疗科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2023 年 7 月 13 日召开第三届董事会第十五次会议和第三届监事会第十四次会 议，审议通过了《关于公司回购股份方案的议案》，同意公司使用不 低于人民币 10,000 万元（含本数）且不超过人民币 20,000 万元（含 本数）的自有资金，以集中竞价交易的方式回购部分公司股份（人民 币普通股（A 股）股票），用于实施员工持股计划及/或股权激励。回 购价格不超过人民币 33.03 元/股（含本数），回购股份的数量和金额 以回购期限届满时实际回购的股份数量和金额为准。回购股份的实施 期限为自公司第三届董事会第十五次会议审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司分别于 2023 年 7 月 13 日、2023 年 7 月 17 日和 2024 年 5 月 31 日披露于巨潮资讯网 （www.cninfo.com.cn）上的《关于公司回购股份方案的公告》（公告 编号：2023-066）、《回购报告 ...

| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2024-063 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 经中国证券监督管理委员会"证监许可[2019]1183 号"文核准， 公司于 2019 年 8 月 16 日公开发行了 470 万张可转债，每张面值 100 元，发行总额 4.70 亿元。 英科医疗科技股份有限公司 2024年第二季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、英科转债（债券代码：123029）转股期为 2020 年 2 月 24 日 至 2025 年 8 月 15 日；当前转股价格为人民币 3.56 元/股。 2、2024 年第二季度，共有 83 张"英科转债"完成转股（票面金 额共计 8,300.00 元人民币），合计转成 2,287 股"英科医疗"股票（股 票代码：300677）。 3、截至 2024 年第二季度末，公司剩余可转债票面总金额为 1,267,300.00 元人民币。 根据《深圳证券交易所创业板 ...